Updating in Apheresis and Atherosclerosis Research

INFORMAZIONI GENERALI
Sede
Sala Convegni Porto Romano
Via Costalunga, 21/31
Fiumicino - Roma
Segreteria Scientifica
Professor Claudia Stefanutti M.D., Ph.D.
Head of Extracorporeal Therapeutic Techniques Unit - Lipid Clinic and
Atherosclerosis Prevention Centre - Immunohematology and Transfusion Medicine
Department of Molecular Medicine - University of Rome ‘Sapienza’
Responsabile dell’U.O.Tecniche Terapeutiche Extracorporee - Centro per lo Studio, Diagnosi e
Terapia delle Dislipidemie e Prevenzione della Aterosclerosi
U.O.C. Immunologia e Medicina Trasfusionale - Dipartimento di Medicina Molecolare
“Sapienza” Università degli Studi di Roma - “Policlinico Umberto I”
V.le del Policlinico 155 - Roma
Italian Multicenter Study on LDL-apheresis Working Group Coordinator
Coordinazione dello Studio Multicentrico Italiano LDL-aferesi (SMILDLa)
V.le del Policlinico 155 - Roma - Tel: 06 499 70578 - Fax: 06 499 70141
[email protected]
Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic
DIsturbances Contrast - MIGHTY MEDIC Coordinator
9th LIPIDCLUB & Therapeutic Apheresis 2014
Interdisciplinary Educational Forum
Updating
in Apheresis and
Atherosclerosis
Research
Segreteria Organizzativa
Centro Italiano Congressi CIC
Corso Trieste, 42 - 00198 Roma - Tel. 06 8412673 - Fax 06 8412687
[email protected] - www.centroitalianocongressi.it
Accreditamento E.C.M.
Il Corso rientra nella normativa che regola l'E.C.M. ed è stato accreditato, sia
per la parte teorica sia per la parte pratica, per:
- medico chirurgo con le seguenti discipline:
cardiologia, malattie metaboliche e diabetologia, medicina interna, nefrologia,
medicina trasfusionale, medicina generale (medici di famiglia)
Il rilascio dei crediti è subordinato alla partecipazione all'intera durata
dei lavori e alla consegna del questionario di valutazione dell’apprendimento
debitamente compilato e firmato
Roma, 6 giugno 2014
I SESSION - Friday morning
II SESSION - Friday afternoon
9.00
Welcome remarks
The MIGHTY MEDIC Working Group General Assembly
9.15
ESC-EAS 2012 Joint Guidelines on Management
of Dyslipidemia, and IAS 2013 guidelines for the treatment
of Severe Hyperlipidemia, Familial Hypercholesterolemia
and HyperLp(a)lipoproteinemia and Cardiovascular Disease
Prevention in Clinical Practice
14.00 1st International Survey: Outcome
9.45
Familial Hypercholesterolemia is underdiagnosed and undertreated.
Can Genetic Diagnosis support Clinicians in the management
of this underestimated very severe disease?
10.15 Lipoprotein(a) as a cardiovascular risk factor: current status.
Diagnosis and Treatment of HyperLp(a)lipoproteinemia
10.45 Coffee break
11.00 Chronic Kidney Disease as Cardiovascular Risk Predictor.
Evidence Based Clinical Management
11.30 Clinical Trials on Novel Lipid Lowering Drugs.
Current Status and Preliminary Results
12.00 Pregnancy in Familial Hypercholesterolemic Women.
Current Managing Approach
12.30 Indications of Therapeutic Apheresis in Pregnant Women.
Clinical Experience
13.00 Current Status of Management of Severe Dyslipidemia in
Children. Diagnosis and Treatment
13.30 Quick lunch
14.30 Upcoming Scientific Activity and Research Projects
15.00 Familial Hypercholesterolaemia: Genetic Testing and Problems
Related to the Development of a Target Therapy
15.30 Antiinflammatory Activity of Lipoprotein Apheresis
16.00 Estrogen-induced Conformational Changes in Low Density
Lipoprotein: a Novel Clue to Understand Atherogenesis in
Women?
16.30 Morphometric Analysis of Circulating Blood Cells in
Atherosclerosis-related Conditions
17.00 Imaging of Cardiovascular Disease. Current Status and Novel
Techniques
17.30 Are Nutraceuticals suitable for Lipid Lowering Treatment and
Prevention of Cardiovascular Disease?
18.00 CME QUESTIONNAIRE
18.30 Closing remarks

Download Report